A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

Bosl, G J; Geller, Nancy L.; Bajorin, Dean F.; Leitner, Stuart P.; Yagoda, A; Golbey, Robert B.; Scher, Howard I.; Vogelzang, N. J.; Auman, James R.; Carey, Robert W.; Fair, William R.; Herr, Harry W.; Morse, Michael J.; Sogani, Pramod C.; Whitmore, Willet F.

doi:10.1016/s0022-5347(17)41358-9

Cited by 11 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies compared bleomycin-free regimens to conventional chemotherapies. The data of these trials were controversial regarding the efficacy: some authors observed similar results [13], while others reported that omission of bleomycin compromised the outcomes [3,14]. Though, all these studies showed agreement in that bleomycin-free regimens were associated with less toxicity compared to those with bleomycin.…”

Section: Discussionmentioning

confidence: 99%

Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Mezvrishvili

Managadze

2006

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Mezvrishvili

Managadze

2006

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…The table presents a range of chemotherapy regimens used in treating good-prognosis non-seminoma; however, clearly specific toxicities do depend on the dose and drugs employed, and advances in oncology have defined regimens producing relatively low toxicity, e.g. those omitting bleomycin with its risk of lung damage, dermatitis and Raynaud's phenomenon [1,13]. Also a randomised trial has suggested that three cycles of bleomycirdetoposide/cisplatin chemotherapy may be as effective as the more standard four cycles in goodprognosis patients [4].…”

Section: Discussionmentioning

confidence: 99%

Initial chemotherapy for stage II testicular non-seminoma

Horwich

Stenning

1994

World J Urol

View full text Add to dashboard Cite

A retrospective survival analysis was performed on 287 patients treated with chemotherapy following orchidectomy for stage II testicular non-seminoma between 1982 and 1986 at a number of centres in the United Kingdom and 1 centre in Norway. A total of 80 patients had lymphadenectomy for a residual mass after chemotherapy. In 17 of these cases the histology was undifferentiated malignancy, in 44 it was differentiated teratoma, in 18 there was necrosis only and in 1 case histology was unknown. The overall survival in 47 patients with initial stage IIA disease (nodes measuring < 2 cm in transverse diameter) was 98% [95% confidence interval (CI), 96%-100%] at 3 years. In 175 patients with stage IIB disease (nodal diameter, 2-5 cm) the 3-year survival was 96% (95% CI, 93%-99%) and in 65 patients with stage IIC disease (nodal diameter, > 5 cm) it was 84% (95% CI, 75%-93%). In stage IIA and stage IIB disease this approach leads to survival equivalent to that obtained with the approach of initial retroperitoneal lymph-node dissection.

show abstract

“…Etoposide (VP-16) has not been systematically evaluated as single agent therapy for malignant melanoma. However, potential synergy with CDDP in an in vitro tumor model [3] and enhanced efficacy of this combination in clinical trials in patients with other tumor types [4,5] prompted a phase II trial of CDDP plus VP-16 in patients with advanced malignant melanoma. Eligibility criteria included: advanced melanoma pathologically confirmed at Memorial SloanKettering Cancer Center and not amenable to potentially curable surgery; age _ 18; Karnofsky performance status _> 60~ estimated survival _> 2 months; bidimensionally measurable indicator lesions; no more than one prior chemotherapy and no prior CDDP; at least one month interval since last radiation, or immunotherapy; white blood cell count _ 4,000//A; platelets _> 150,000/#1; creatinine _< 1.3 rag%; creatinine clearance > 60 ml/min/1.7 m2; bilirubin _< 1.5 mg%; and, informed consent.…”

Section: Introduction Methodsmentioning

confidence: 99%

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma

et al. 1991

View full text Add to dashboard Cite

Fourteen patients with metastatic melanoma were treated with cisplatin and etoposide by bolus intravenous infusion daily for 5 consecutive days each month. All patients were evaluable for toxicity and twelve for response. Eight patients were treated with cisplatin 20 mg/m 2 and etoposide 100 mg/m 2 daily. Because of excessive myelosuppression, the daily dose of etoposide was reduced to 75 mg/m 2 in the remaining six patients. There were no major responses among 12 evaluable patients (major response rate _< 24% with 95% confidence). The median time to progression was one month. One patient with a liver metastasis had a minor response lasting 6 + months. The combination of cisplatin and etoposide in these doses and schedule lacked sufficient clinical efficacy in the treatment of metastatic melanoma.

show abstract

A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

Cited by 11 publications

References 0 publications

Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Initial chemotherapy for stage II testicular non-seminoma

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma

Contact Info

Product

Resources

About